[Modern Approaches to Prevention of Thromboembolic Complications in Patients With Nonvalvular Atrial Fibrillation With a Direct Thrombin Inhibitor Dabigatran].
of recently completed clinical studies and preliminary results of still ongoing studies that support safety and efficacy of dabigatran in patients with nonvalvular atrial fibrillation are under discussion in this article. Currently available data on clinical use of a specific dabigatran antidote idarucizumab are also presented.